166 related articles for article (PubMed ID: 33640906)
21. Hepatectomy leads to loss of TRAIL-expressing liver NK cells via downregulation of the CXCL9-CXCR3 axis in mice.
Yano T; Ohira M; Nakano R; Tanaka Y; Ohdan H
PLoS One; 2017; 12(10):e0186997. PubMed ID: 29088306
[TBL] [Abstract][Full Text] [Related]
22. Increased T-bet+ cytotoxic effectors and type I interferon-mediated processes in chronic graft-versus-host disease of the oral mucosa.
Imanguli MM; Swaim WD; League SC; Gress RE; Pavletic SZ; Hakim FT
Blood; 2009 Apr; 113(15):3620-30. PubMed ID: 19168793
[TBL] [Abstract][Full Text] [Related]
23. The CXCL9/10/11-CXCR3 axis as a predictor of COVID-19 progression: a prospective, case-control study.
Çelik N; Çelik O; Laloğlu E; Özkaya A
Rev Soc Bras Med Trop; 2023; 56():e01282023. PubMed ID: 37493737
[TBL] [Abstract][Full Text] [Related]
24. Role of CXCL9/CXCR3 chemokine biology during pathogenesis of acute lung allograft rejection.
Belperio JA; Keane MP; Burdick MD; Lynch JP; Zisman DA; Xue YY; Li K; Ardehali A; Ross DJ; Strieter RM
J Immunol; 2003 Nov; 171(9):4844-52. PubMed ID: 14568964
[TBL] [Abstract][Full Text] [Related]
25. CXCR3 and CCR5 chemokines in induced sputum from patients with COPD.
Costa C; Rufino R; Traves SL; Lapa E Silva JR; Barnes PJ; Donnelly LE
Chest; 2008 Jan; 133(1):26-33. PubMed ID: 17925429
[TBL] [Abstract][Full Text] [Related]
26. Risk-factor analysis for predicting progressive- or quiescent-type chronic graft-versus-host disease in a patient cohort with a history of acute graft-versus-host disease after allogeneic stem cell transplantation.
Sohn SK; Kim DH; Baek JH; Kim JG; Lee KB; Lee KH; Lee JH; Choi SJ; Lee JH; Shin IH
Bone Marrow Transplant; 2006 Apr; 37(7):699-708. PubMed ID: 16501588
[TBL] [Abstract][Full Text] [Related]
27. Intracellular domains of CXCR3 that mediate CXCL9, CXCL10, and CXCL11 function.
Colvin RA; Campanella GS; Sun J; Luster AD
J Biol Chem; 2004 Jul; 279(29):30219-27. PubMed ID: 15150261
[TBL] [Abstract][Full Text] [Related]
28. Optic neuritis: chemokine receptor CXCR3 and its ligands.
Sørensen TL; Roed H; Sellebjerg F
Br J Ophthalmol; 2004 Sep; 88(9):1146-8. PubMed ID: 15317705
[TBL] [Abstract][Full Text] [Related]
29. Risk Factors and Outcome of Chronic Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation-Results from a Single-Center Observational Study.
Grube M; Holler E; Weber D; Holler B; Herr W; Wolff D
Biol Blood Marrow Transplant; 2016 Oct; 22(10):1781-1791. PubMed ID: 27343720
[TBL] [Abstract][Full Text] [Related]
30. CXCR3 Ligands in Cancer and Autoimmunity, Chemoattraction of Effector T Cells, and Beyond.
Karin N
Front Immunol; 2020; 11():976. PubMed ID: 32547545
[TBL] [Abstract][Full Text] [Related]
31. Polymorphisms of CXCR3-binding chemokines in type 1 diabetes.
Brück P; Bartsch W; Penna-Martinez M; Kahles H; Seidl C; Böhme A; Badenhoop K; Ramos-Lopez E
Hum Immunol; 2009 Jul; 70(7):552-5. PubMed ID: 19410617
[TBL] [Abstract][Full Text] [Related]
32. CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - A target for novel cancer therapy.
Tokunaga R; Zhang W; Naseem M; Puccini A; Berger MD; Soni S; McSkane M; Baba H; Lenz HJ
Cancer Treat Rev; 2018 Feb; 63():40-47. PubMed ID: 29207310
[TBL] [Abstract][Full Text] [Related]
33. Genetic variation in recipient B-cell activating factor modulates phenotype of GVHD.
Clark WB; Brown-Gentry KD; Crawford DC; Fan KH; Snavely J; Chen H; Savani BN; Kassim A; Greer JP; Schuening FG; Engelhardt BG; Jagasia MH
Blood; 2011 Jul; 118(4):1140-4. PubMed ID: 21628416
[TBL] [Abstract][Full Text] [Related]
34. Study on the relationship between CXCR3 and its ligands and tubal tuberculosis.
Sun H; Fan J; Shang X; Tuohetaerbaike B; Li Y; Lv J; Wang Y; Wang L; Wang J; Ma X
Life Sci; 2021 May; 272():119047. PubMed ID: 33454369
[TBL] [Abstract][Full Text] [Related]
35. Critical role for CXCR3 chemokine biology in the pathogenesis of bronchiolitis obliterans syndrome.
Belperio JA; Keane MP; Burdick MD; Lynch JP; Xue YY; Li K; Ross DJ; Strieter RM
J Immunol; 2002 Jul; 169(2):1037-49. PubMed ID: 12097412
[TBL] [Abstract][Full Text] [Related]
36. Review: The chemokine receptor CXCR3 and its ligands CXCL9, CXCL10 and CXCL11 in neuroimmunity--a tale of conflict and conundrum.
Müller M; Carter S; Hofer MJ; Campbell IL
Neuropathol Appl Neurobiol; 2010 Aug; 36(5):368-87. PubMed ID: 20487305
[TBL] [Abstract][Full Text] [Related]
37. A correlation study between gene polymorphism of Th cell expressed chemokine receptor CXCR3 and its ligand levels with HCV infection prognosis.
Lu Y; Lin LY; Tan JG; Deng HP; Li XH; Zhang Z; Li Y; Zhou Z; Xu X; Xie X; Mei SJ
Eur Rev Med Pharmacol Sci; 2017 Mar; 21(6):1290-1295. PubMed ID: 28387899
[TBL] [Abstract][Full Text] [Related]
38. Effect of JAK Inhibitors on Release of CXCL9, CXCL10 and CXCL11 from Human Airway Epithelial Cells.
Fenwick PS; Macedo P; Kilty IC; Barnes PJ; Donnelly LE
PLoS One; 2015; 10(6):e0128757. PubMed ID: 26090665
[TBL] [Abstract][Full Text] [Related]
39. Elevated serum levels of the CXCR3 chemokine ITAC are associated with the development of transplant coronary artery disease.
Kao J; Kobashigawa J; Fishbein MC; MacLellan WR; Burdick MD; Belperio JA; Strieter RM
Circulation; 2003 Apr; 107(15):1958-61. PubMed ID: 12695288
[TBL] [Abstract][Full Text] [Related]
40. CXCL9, CXCL10 and CXCL11 polymorphisms are associated with sustained virologic response in HIV/HCV-coinfected patients.
Pineda-Tenor D; Berenguer J; Jiménez-Sousa MA; Guzmán-Fulgencio M; Aldámiz-Echevarria T; Carrero A; García-Álvarez M; Diez C; Tejerina F; Briz V; Resino S
J Clin Virol; 2014 Nov; 61(3):423-9. PubMed ID: 25218243
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
